



November 5, 2014

## **Chembio to Host Third Quarter 2014 Earnings Conference Call and Webcast Live on Thursday, November 6, 2014**

Category: Baystreet Newswire

Company: Issuer Direct

ID: 422546

Date: Wednesday, November 05, 2014

Ticker: NASDAQ:CEMI

MEDFORD, NY / ACCESSWIRE / November 5, 2014 / Chembio Diagnostics, Inc. (NASDAQ: CEMI) will host a conference call and live webcast to discuss the results of the third quarter 2014, to be held Thursday, November 6, 2014 at 10:00 AM Eastern Time.

To participate in this event, dial 877-407-0778 domestically, or 201-689-8565 internationally, approximately 5 to 10 minutes before the beginning of the call. Additionally, you can listen to the event online at [www.investorcalendar.com/IC/CEPage.asp?ID=173358](http://www.investorcalendar.com/IC/CEPage.asp?ID=173358).

If you are unable to participate during the live webcast, the event archive will be available at [www.investorcalendar.com/IC/CEPage.asp?ID=173358](http://www.investorcalendar.com/IC/CEPage.asp?ID=173358) or [chembio.com](http://chembio.com).

You may access the teleconference replay by dialing 877-660-6853 domestically or 201-612-7415 internationally, referencing conference ID #13594205. The replay will be available beginning approximately 2 hours after the completion of the live event, ending at midnight Eastern on November 13, 2014.

### About Chembio Diagnostics

Chembio Diagnostics, Inc. develops, manufactures, licenses and markets proprietary rapid diagnostic tests in the growing \$8.0 billion point-of-care testing market. Chembio markets its DPP(R) HIV 1/2 Assay and HIV 1/2 STAT-PAK(R) Assay in the U.S. and internationally. The Company's SURE CHECK(R) HIV 1/2 Assay is marketed exclusively in the U.S. as Clearview(R) Complete. Outside the U.S., Chembio markets its SURE CHECK(R) HIV 1/2 Assays through distributors.

Chembio has developed a patented point-of-care test platform technology, the Dual Path Platform (DPP(R)) technology, which has significant advantages over lateral-flow technologies. This technology is providing Chembio with a significant pipeline of business opportunities for the development and manufacture of new products.

Headquartered in Medford, NY, Chembio is licensed by the U.S. Food and Drug Administration (FDA) as well as the U.S. Department of Agriculture (USDA), and is certified for the global market under the International Standards Organization (ISO) directive 13485. Chembio Diagnostic Systems, Inc. is a wholly-owned subsidiary of Chembio Diagnostics, Inc. For more information, please visit: [www.chembio.com](http://www.chembio.com).

SOURCE: Chembio Diagnostics, Inc.

News Provided by Acquire Media